Basile, Jan

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial

Gerstein, H. C., Colhoun, H. M., Dagenais, G. R., Diaz, R., Lakshmanan, M., Pais, P., Probstfield, J., Riesmeyer, J. S., Riddle, M. C., Rydén, L., et al. (2019) · The Lancet

Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 3,163

Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial

Ismail-Beigi, F., Craven, T., Banerji, M. A., Basile, J., Calles, J., Cohen, R. M., Cuddihy, R., Cushman, W. C., Genuth, S., Grimm, R. H., et al. (2010) · The Lancet

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 1,428

Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial

Gerstein, H. C., Colhoun, H. M., Dagenais, G. R., Diaz, R., Lakshmanan, M., Pais, P., Probstfield, J., Botros, F. T., Riddle, M. C., Rydén, L., et al. (2019) · The Lancet

Diabetes Treatment and ManagementChronic Kidney Disease and Diabetes

Cited by 638

Self-Measured Blood Pressure Monitoring at Home: A Joint Policy Statement From the American Heart Association and American Medical Association

Shimbo, D., Artinian, N. T., Basile, J. N., Krakoff, L. R., Margolis, K. L., Rakotz, M. K., Wozniak, G., & On behalf of the American Heart Association and the American Medical Association (2020) · Circulation

Blood Pressure and Hypertension StudiesClinical practice guidelines implementation

Cited by 389

Effect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trial

Cukierman-Yaffe, T., Gerstein, H. C., Colhoun, H. M., Diaz, R., García-Pérez, L.-E., Lakshmanan, M., Bethel, A., Xavier, D., Probstfield, J., Riddle, M. C., et al. (2020) · The Lancet Neurology

Diabetes Treatment and ManagementDementia and Cognitive Impairment Research

Cited by 300

Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS‐CVOT design and baseline characteristics

Nicholls, S. J., Bhatt, D. L., Buse, J. B., Prato, S. D., Kahn, S. E., Lincoff, A. M., McGuire, D. K., Nauck, M. A., Nissen, S. E., Sattar, N., et al. (2024) · American Heart Journal

Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 248

Endovascular Ultrasound Renal Denervation to Treat Hypertension: The RADIANCE II Randomized Clinical Trial

Azizi, M., Saxena, M., Wang, Y., Jenkins, J. S., Devireddy, C., Rader, F., Fisher, N. D. L., Schmieder, R. E., Mahfoud, F., Lindsey, J., et al. (2023) · JAMA

Blood Pressure and Hypertension StudiesRenal and Vascular Pathologies

Cited by 199

Impact of intensive glycemic control on the incidence of atrial fibrillation and associated cardiovascular outcomes in patients with type 2 diabetes mellitus (from the Action to Control Cardiovascular Risk in Diabetes Study)

Fatemi, O., Yuriditsky, E., Tsioufis, C., Tsachris, D., Morgan, T., Basile, J., Bigger, T., Cushman, W., Goff, D., Soliman, E. Z., et al. (2014) · The American Journal of Cardiology

Atrial Fibrillation Management and OutcomesDiabetes Treatment and Management

Cited by 173

Clinical events in high-risk hypertensive patients randomly assigned to calcium channel blocker versus angiotensin-converting enzyme inhibitor in the antihypertensive and lipid-lowering treatment to prevent heart attack trial

Leenen, F. H. H., Nwachuku, C. E., Black, H. R., Cushman, W. C., Davis, B. R., Simpson, L. M., Alderman, M. H., Atlas, S. A., Basile, J. N., Cuyjet, A. B., et al. (2006) · Hypertension

Blood Pressure and Hypertension StudiesRenin-Angiotensin System Studies

Cited by 171

The effect of dulaglutide on stroke: an exploratory analysis of the REWIND trial

Gerstein, H. C., Hart, R., Colhoun, H. M., Diaz, R., Lakshmanan, M., Botros, F. T., Probstfield, J., Riddle, M. C., Rydén, L., Atisso, C. M., et al. (2020) · The Lancet Diabetes & Endocrinology

Diabetes Treatment and ManagementAcute Ischemic Stroke Management

Cited by 137

Rationale and Design for the Blood Pressure Intervention of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial

Cushman, W. C., Grimm, R. H., Cutler, J. A., Evans, G. W., Capes, S., Corson, M. A., Sadler, L. S., Alderman, M. H., Peterson, K., Bertoni, A., et al. (2007) · The American Journal of Cardiology

Blood Pressure and Hypertension StudiesDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 123

Cardiovascular Outcomes Using Doxazosin vs. Chlorthalidone for the Treatment of Hypertension in Older Adults With and Without Glucose Disorders: A Report From the ALLHAT Study

Barzilay, J. I., Davis, B. R., Bettencourt, J., Margolis, K. L., Goff, D. C., Black, H., Habib, G., Ellsworth, A., Force, R. W., Wiegmann, T., et al. (2004) · The Journal of Clinical Hypertension

Blood Pressure and Hypertension StudiesDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 70

Erectile function in men with type 2 diabetes treated with dulaglutide: an exploratory analysis of the REWIND placebo-controlled randomised trial

Bajaj, H. S., Gerstein, H. C., Rao-Melacini, P., Basile, J., Colhoun, H., Conget, I., Cushman, W. C., Dagenais, G. R., Franek, E., Hanefeld, M., et al. (2021) · The Lancet Diabetes & Endocrinology

Sexual function and dysfunction studiesDiabetes Treatment and Management

Cited by 56

Total cardiovascular or fatal events in people with type 2 diabetes and cardiovascular risk factors treated with dulaglutide in the REWIND trail: a post hoc analysis

Dagenais, G. R., Rydén, L., Leiter, L. A., Lakshmanan, M., Dyal, L., Probstfield, J. L., Atisso, C. M., Shaw, J. E., Conget, I., Cushman, W. C., et al. (2020) · Cardiovascular Diabetology

Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 35